-
The endothelin receptor antagonist bosentan has been shown to improve exercise tolerance, hemodynamics, and clinical deterioration in trials of patients with advanced symptoms due to pulmonary hypertension (WHO functional class III and IV).
-
Following successful reperfusion for acute myocardial infarction (MI) with primary percutaneous coronary intervention (PCI), the persistence of impaired perfusion portends a poor prognosis.
-
It has long been believed, with considerable substantiation, that women have poorer results of percutaneous interventions (PCI) than men, with higher morbidity and mortality rates.
-
The atrial fibrillation and congestive heart Failure (AF-CHF) trial was designed to test the hypothesis that a treatment strategy that involved rhythm control would be superior to rate control in patients with heart failure and left ventricular systolic dysfunction.
-
Patients with diabetes mellitus make up a substantial proportion of those undergoing percutaneous coronary intervention (PCI), and they are at higher risk for post-procedural complications.
-
There have been no major therapeutic steps added for the management of acute gouty arthritis (AGA) for over 30 years.
-
Duloxetine is the first serotonin norepinephrine reuptake inhibitor (SNRI) to be approved for the treatment of fibromyalgia.
-
After 7.3 years of treatment and follow-up, a combination pill of folic acid, vitamin B6 and vitamin B12 did not reduce a combined endpoint of total cardiovascular events among high-risk women despite significant homocysteine lowering.
-
Standard eradication therapy for H. pylori in the U.S. has involved use of a proton pump inhibitor (PPI) plus clarithromycin and either amoxicillin or an imidazole (metronidazole).
-
Shingles vaccine added to CDC list of vaccines for adults 60 and older; CDC recommends Tdap for postpartum women; new study suggests sequential therapy with antibiotics for H. pylori may be more effective than standard therapy; FDA Actions.